Compare Abeona Therapeutics Inc (ABEO) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.76. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | EMB | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $97.74 |
52-Week Low | $4.17 | $91.52 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EMB trades at $96.35, showing minimal daily movement with a 0.16% gain. The technical outlook is neutral, supported by a bullish moving average signal but offset by neutral oscillators and sell signals from the ADX. Recent corporate actions include scheduled dividend payments in 2026, though key financial ratios are unavailable for fundamental assessment.
The outlook for EMB hinges on emerging market bond dynamics and Federal Reserve policy, with news highlighting yield appeal but also sovereign default risks. Key risks include geopolitical tensions and inflation, while institutional interest in EM bond ETFs suggests underlying demand. Investors should weigh high-yield potential against macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
